RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-ESCALATION TRIAL OF A HUMANIZED RESPIRATORY SYNCYTIAL VIRUS (RSV) MONOCLONAL ANTIBODY (MEDI-493) IN HIGH RISK INFANTS. • 768

Autor: T. Rhodes, E. Connor, Leonard E. Weisman, K. N. Siva Subramanian
Rok vydání: 1997
Předmět:
Zdroj: Pediatric Research. 41:130-130
ISSN: 1530-0447
0031-3998
DOI: 10.1203/00006450-199704001-00788
Popis: AIM: MEDI-493 is directed against the F protein of RSVand is broadly reactive against RSV in vitro. Serum levels of 25-30 ug/ml result in a 2-log reduction of RSV in cotton rats. This study describes the safety, immunogenicity and pharmacokinetics of MEDI-493 in high risk children.
Databáze: OpenAIRE